SALT LAKE CITY, Oct. 18 /PRNewswire-FirstCall/ -- Diabetic Treatment Centers of America, Inc. (BULLETIN BOARD: DBTC) , today announced the execution of an exclusive rights agreement with Diabetes Medical Development Corporation.
“This Agreement is a significant step in our plan to provide some of the most advanced and effective therapies available in the world to our patients. The therapies supported by these proven, patented technologies will greatly improve the quality of life for persons suffering from severe diabetes and other metabolic disorders,” said Arden Oliphant, President and CEO, Diabetic Treatment Centers of America, Inc.
This Agreement which was executed by both parties provides certain exclusive rights to patented technologies that are used to treat diabetes and other metabolic disorders.
About Diabetic Treatment Centers of America, Inc. - Based in Salt Lake City, Utah, DTC of America, Inc. is dedicated to providing diabetics with significantly improved health and a better quality of life.
Safe Harbor Statement
This news release may include forward-looking statements within the meaning of Section 27a of the United States Securities Act of 1933, as amended, and Section 21e of the United States Securities and Exchange Act of 1934, as amended, with respect to achieving corporate objectives, developing additional project interests, the company’s analysis of opportunities in the acquisition and development of various project interests and certain other matters. These statements are made under the “Safe Harbor” provisions of the United States Private Securities Litigation Reform Act of 1995 and involve risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements contained herein.
For further information, please contact Arden Oliphant of Diabetic Treatment Centers of America, Inc., +1-801-207-1816.
botulinum toxin div>
CONTACT: Arden Oliphant of Diabetic Treatment Centers of America, Inc.,+1-801-207-1816